PERS&O (PERsistent sitagliptin treatment & outcomes): Observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Buonaiuto, Giulia ^a   De Mori, Valentina ^a   Braus, Alessandra ^b   Balini, Annalisa ^a   Berzi, Denise ^a   Carpinteri, Rita ^a   Forloni, Franco ^a   Meregalli, Giancarla ^a   Ronco, Gian Luca ^c   Bossi, Antonio C ^a  

^a Endocrine Unit   (Italy)

^b Oncology Unit   (Italy)

^c IT HealthCare Senior Consultant   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE DURATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84988667387     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2016-000216     Document Type: Article

References (38)

1. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 2013;14:2047-58.
2. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007;30:1344-50.
3. Scirica BM, Bhatt DL, Braunwald E, et al, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
4. Zannad F, Cannon CP, Cushman WC, et al, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicenter, randomised, double-blind trial. Lancet 2015;385:2067-76.
5. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-97.
6. Giorda CB, Picariello R, Tartaglino B, et al. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. BMJ Open 2015;5:e007959.
7. Fadini GP, Avogaro A, Degli Esposti L, et al, OsMed Health-DB Network. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J 2015;36:2454-62.
8. Monami M, Ahrén B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20.
9. Green JB, Bethel MA, Armstrong PW, et al, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
10. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
11. [No authors listed]. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
12. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19.
13. Stevens RJ, Kothari V, Adler AI, et al, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
14. https://www.dtu.ox.ac.uk/riskengine/download.php (accessed 15 May 2016).
15. International Diabetes Federation. Global guidelines for type 2 diabetes. http://www.idf.org/node/1283 (accessed 15 May 2016).
16. Janssen F, Kunst AE, Netherlands Epidemiology and Demography Compression of Morbidity research group. Cohort patterns in mortality trends among the elderly in seven European countries, 1950-1999. Int J Epidemiol 2005;34:1149-59.
17. Pagano E, Gray A, Rosato R, et al. Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, Italy. Diabetologia 2013;56:1726-34.
18. Sacket DL, Richardson WS, Rosenberg W. Evidence-based medicine: how to practice and teach EBM. New York: Churchill Livingstone, 1997.
19. Diggle PJ. Testing for random dropouts in repeated measurement data. Biometrics 1989;45:1255-8.
20. Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies:how much is too much? Eur J Epidemiol 2004;19:751-60.
21. Bacchetti P. Current sample size conventions: flaws, harms, and alternatives. BMC Med 2010;8:17.
22. Bacchetti P, Wolf LE, Segal MR, et al. Ethics and sample size. Am J Epidemiol 2005;161:105-10.
23. Avogaro A, Giorda C, Maggini M, et al, Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007;30:1241-7.
24. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes:a systematic review and metaanalysis of 98 trials with 24 163 patients. BMJ Open 2015;5:e005892.
25. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
26. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
27. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18.
28. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-82.
29. Matsushima Y, Takeshita Y, Kita Y, et al. Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial. BMJ Open Diabetes Res Care 2016;4:e000190.
30. Price D, Brusselle G, Roche N, et al. Real-world research and its importance in respiratory medicine. Breathe (Sheff) 2015;11:27-38.
31. Laken MA, Dawson R, Engelman O, et al. Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension. J Am Soc Hypertens 2013;7:95-101.
32. Fujita K, Sasaki Y. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the ‘real world’. Drug Metab Pharmacokinet 2014;29:20-8.
33. Johnson M, Jones R, Freeman C, et al. Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence. Diabet Med 2013;30:3-15.
34. Fu AZ, Johnston SS, Ghannam A, et al. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care 2016;39:726-34.
35. Filion KB, Suissa S. DPP-4 inhibitors and heart failure:some reassurance, some uncertainty. Diabetes Care 2016;39:735-7.
36. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573
37. Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study. BMJ 2015;351:h5441.
38. Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study. BMJ Open 2015;5:e008503.